中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
5期
971-973
,共3页
黄军%袁盾%李岩%Walter A Hall%李波%龙小艳
黃軍%袁盾%李巖%Walter A Hall%李波%龍小豔
황군%원순%리암%Walter A Hall%리파%룡소염
脑胶质瘤%免疫治疗%加强对流投递%模型,动物
腦膠質瘤%免疫治療%加彊對流投遞%模型,動物
뇌효질류%면역치료%가강대류투체%모형,동물
Glioblastoma%Immunotherapy%Convection-enhanced delivery%Model,animal
目的 观察免疫毒素DTATEGF通过渗透泵加强对流释放(CED)给药对裸鼠颅内人胶质母细胞瘤的治疗效果.方法 噻唑蓝(MTT)比色法检测DTATEGF对体外培养的Ln229细胞株的增殖抑制作用.建立裸小鼠颅内荧光素酶标记的人胶质母细胞瘤模型,将1μg的DTATEGF和对照Bickel3通过渗透泵CED投递处理颅内肿瘤检测肿瘤的荧光信号强度,小鼠的存活时间及肿瘤标本苏木素-伊红(HE)染色形态学检测.结果 DTATEGF显著抑制Ln229-luc细胞增殖,其半数抑制剂量(IC50)小于0.001 nmol/L.CED投递药物实验中,小鼠很好地耐受渗透泵；DTATEGF治疗组小鼠的中位生存期85 d,与对照组生存期(67 d)比较差异有统计学意义(P＜0.01).结论 DTATEGF显著抑制Ln229-luc细胞株增殖,抑制裸小鼠人胶质母细胞瘤生长,延长荷瘤小鼠的生存.
目的 觀察免疫毒素DTATEGF通過滲透泵加彊對流釋放(CED)給藥對裸鼠顱內人膠質母細胞瘤的治療效果.方法 噻唑藍(MTT)比色法檢測DTATEGF對體外培養的Ln229細胞株的增殖抑製作用.建立裸小鼠顱內熒光素酶標記的人膠質母細胞瘤模型,將1μg的DTATEGF和對照Bickel3通過滲透泵CED投遞處理顱內腫瘤檢測腫瘤的熒光信號彊度,小鼠的存活時間及腫瘤標本囌木素-伊紅(HE)染色形態學檢測.結果 DTATEGF顯著抑製Ln229-luc細胞增殖,其半數抑製劑量(IC50)小于0.001 nmol/L.CED投遞藥物實驗中,小鼠很好地耐受滲透泵；DTATEGF治療組小鼠的中位生存期85 d,與對照組生存期(67 d)比較差異有統計學意義(P＜0.01).結論 DTATEGF顯著抑製Ln229-luc細胞株增殖,抑製裸小鼠人膠質母細胞瘤生長,延長荷瘤小鼠的生存.
목적 관찰면역독소DTATEGF통과삼투빙가강대류석방(CED)급약대라서로내인효질모세포류적치료효과.방법 새서람(MTT)비색법검측DTATEGF대체외배양적Ln229세포주적증식억제작용.건립라소서로내형광소매표기적인효질모세포류모형,장1μg적DTATEGF화대조Bickel3통과삼투빙CED투체처리로내종류검측종류적형광신호강도,소서적존활시간급종류표본소목소-이홍(HE)염색형태학검측.결과 DTATEGF현저억제Ln229-luc세포증식,기반수억제제량(IC50)소우0.001 nmol/L.CED투체약물실험중,소서흔호지내수삼투빙；DTATEGF치료조소서적중위생존기85 d,여대조조생존기(67 d)비교차이유통계학의의(P＜0.01).결론 DTATEGF현저억제Ln229-luc세포주증식,억제라소서인효질모세포류생장,연장하류소서적생존.
Objective To investigate the anticancer effect of the bispecific immunotoxin DTATEGF in vitro and in vivo when delivered bv convection-enhanced delivery (CED) via an osmotic minipump in a human glioblastoma brain tumor mouse xenograft model.Methods The effects of the immunotoxins were tested for their ability to inhibit the proliferation of Ln229-luc cells in vitro by methyl thiazol tetrazolium (MTT) assay.On a xenograft intracranial model,1 μg of DTATEGF or eontrol Bickel3 was delivered intracranially by CED via an osmotic minipump.The bioluminescent imaging (BLI) was performed and Kaplan-Meier survival curves were generated.The brain tumor samples were stained by hematoxylin and eosin for histopathological assessment.Results In vitro,DTATEGF could kill Ln229-luc cells and showed an 50％ inhibitory dose(IC50) less than 0.001 nmol/L.In vivo,mice with tumors were treated intracranially with drug via CED where the treatment was successful in providing a survival benefit with the median survival of mice treated with DTATEGF being significantly prolonged relative to controls (85 vs.67 days,P ＜0.01).Conclusion DTATEGF kills the Ln229-luc cell line in vitro,and when it is delivered via CED intracranially,it is highly efficacious against human glioblastoma brain tumors.
